Nearly 30 years of research findings stated that adenosine adjust ischemia. Although, adenosine use for treatment has not been accepted clinically in wide manner, also there have no many clinical trials. Aims: study the effects of adenosine and dipyridamole on total Antioxidant Capacity (TAC), Adenosine Deaminase (ADA), GSH (Glutathione), TNF - a (tumor necrosis factor Alpha) and IL-6 (Interleukin 6) in rabbits. Material and methods: Thirty five male rabbits were included in the study. The animals were divided into 3 groups: Group one(5 animals): injected (i.p) with 2 ml of distilled water/day (control group). Group two (15 animals): were treated by intraperitoneal injection of adenosine, they were divided into 3 sub groups (5 animals) according to adenosine dose:1 mg/kg, 2mg/kg and 4 mg/kg.Group 3 (15 animals): were treated by dipyridamole orally, they were divided into 3 sub groups (5 animals) according to dipyridamole dose:4 mg/kg, 8 mg/kg and 12 mg/kg. Total Antioxidant Capacity Assay kit, Adenosine Deaminase (ADA) colorimetric Assay kit, Rabbit IL-6 (Interleukin 6) ELIISA kit, Rabbit TNF - a (tumor necrosis factor Alpha), GSH (Glutathione) ELISA kits were used. Results: ANOVA Test and Duncan’s Multiple Range Test were applied between study groups. In comparison among adenosine, dipyridamole and control groups, highly significant differences were found among them in TAC,ADA and GSH levels while no significant differences were found in TNF -a and IL-6 levels among all groups. Conclusion: both adenosine, dipyridamole cause reduction in total Antioxidant Capacity together with increase in glutathione levels and Adenosine Deaminase.